NasdaqCM - Delayed Quote USD

Evoke Pharma, Inc. (EVOK)

0.4685 -0.0460 (-8.94%)
At close: 4:00 PM EDT
0.4959 +0.03 (+5.85%)
After hours: 4:04 PM EDT
Loading Chart for EVOK
DELL
  • Previous Close 0.5145
  • Open 0.4980
  • Bid 0.3268 x 200
  • Ask 0.6090 x 200
  • Day's Range 0.4685 - 0.5030
  • 52 Week Range 0.4160 - 2.4000
  • Volume 1,889
  • Avg. Volume 47,361
  • Market Cap (intraday) 3.972M
  • Beta (5Y Monthly) 0.30
  • PE Ratio (TTM) --
  • EPS (TTM) -2.3300
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

www.evokepharma.com

4

Full Time Employees

December 31

Fiscal Year Ends

Recent News: EVOK

Performance Overview: EVOK

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EVOK
55.38%
S&P 500
4.14%

1-Year Return

EVOK
75.34%
S&P 500
19.55%

3-Year Return

EVOK
97.63%
S&P 500
18.68%

5-Year Return

EVOK
94.64%
S&P 500
70.99%

Compare To: EVOK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EVOK

Valuation Measures

As of 4/18/2024
  • Market Cap

    4.06M

  • Enterprise Value

    4.32M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.31

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    0.83

  • Enterprise Value/EBITDA

    -0.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -150.41%

  • Return on Assets (ttm)

    -49.09%

  • Return on Equity (ttm)

    -1,035.44%

  • Revenue (ttm)

    5.18M

  • Net Income Avi to Common (ttm)

    -7.79M

  • Diluted EPS (ttm)

    -2.3300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.74M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.53M

Research Analysis: EVOK

Fair Value

Overvalued
% Return
0.4685 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

People Also Watch